IOVA Earnings Iovance Biotherapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–25 of 25
| Q2 2026 | 2026-06-30 | -0.29 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.19 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -1.09 | 2026-02-24 | 10-K |
| Q2 2026 | 2025-06-30 | -0.69 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.36 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.28 | 2026-02-24 | 10-K |
| Q3 2024 | 2024-09-30 | -1.03 | 2024-11-07 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.76 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.42 | 2025-05-08 | 10-Q |
| FY 2025 | 2023-12-31 | -1.89 | 2026-02-24 | 10-K |
| Q3 2024 | 2023-09-30 | -1.44 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.98 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.50 | 2024-05-09 | 10-Q |
| FY 2024 | 2022-12-31 | -2.49 | 2025-02-27 | 10-K |
| Q3 2023 | 2022-09-30 | -1.85 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.21 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.58 | 2023-05-10 | 10-Q |
| FY 2023 | 2021-12-31 | -2.23 | 2024-02-28 | 10-K |
| Q3 2022 | 2021-09-30 | -1.60 | 2022-11-03 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.04 | 2022-08-04 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.51 | 2022-05-05 | 10-Q |
| FY 2022 | 2020-12-31 | -1.88 | 2023-02-28 | 10-K |
| Q3 2021 | 2020-09-30 | -1.41 | 2021-11-04 | 10-Q |
| Q2 2021 | 2020-06-30 | -1.02 | 2021-08-05 | 10-Q |
| FY 2021 | 2019-12-31 | -1.59 | 2022-02-24 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.